Eli Lilly and Co. has launched a national campaign aimed at reducing the stigma surrounding obesity, using personal stories and visual symbolism to highlight the challenges faced by people living with the disease.
Read MoreEli Lilly and Co. on Friday, Nov. 21 became the first health care company to surpass a $1 trillion market valuation, driven by intense investor demand for its fast-growing weight-loss drug portfolio.
Read MoreShares of Eli Lilly and Novo Nordisk fell Friday, Oct. 17 after Pres. Donald Trump said the price of the weight-loss drug Ozempic could soon drop to $150 a month.
Read MoreIndianapolis-based Eli Lilly and Co. shares fell Thursday, Aug. 7 following the pharmaceutical company’s second-quarter earnings report, alongside results from a closely watched trial of its experimental weight-loss pill.
Read MoreAccording to a new BioCrossroads report, in 2024, Indiana was the largest national exporter of life science products and the industry generated $99 billion in economic activity.
Read MoreTo fight cheaper alternative versions of its weight loss drug, Eli Lilly & Co. have lowered prices of Zepbound vials.
Read MoreEli Lilly and Company has announced topline results from the SURMOUNT-5 phase 3b open-label randomized clinical trial.
Read MoreShares of Eli Lilly and Co. took a two-day slide after competitor Roche announced positive results in an early-stage study on its obesity drug.
Read MoreThe U.S. Food and Drug Administration approved Eli Lilly and Company’s Zepbound injection, the first and only obesity treatment of its kind that activates both glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 hormone receptors.
Read More
